Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HCW BiologicsHCWB +3.09%37 Equity-to-Asset is 0.21 as of Mar. 2026, which is 69% below its 10-year median of 0.68. GuruFocus rates HCWB with a GF Score™ of 37/100 and a GF Value™ of $43.71 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,416 Biotechnology companies, HCW Biologics ranks worse than 81.99% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. HCW Biologics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $5.76 Mil. HCW Biologics's Total Assets for the quarter that ended in Mar. 2026 was $27.34 Mil.
Therefore, HCW Biologics's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.21.
The historical rank and industry rank for HCW Biologics's Equity-to-Asset or its related term are showing as below:
HCWB'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.38 Med: 0.68 Max: 0.97
Current: 0.21
During the past 7 years, the highest Equity to Asset Ratio of HCW Biologics was 0.97. The lowest was -0.38. And the median was 0.68.
HCWB's Equity-to-Asset is ranked worse than 81.99% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs HCWB: 0.21
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
HCW Biologics Equity-to-Asset Related Terms
HCW Biologics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for HCW Biologics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCWB vs GOVX, GLMD, SXTP: Equity-to-Asset Comparison
For the Biotechnology subindustry, HCW Biologics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where HCW Biologics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
HCW Biologics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCW Biologics (HCWB) has a Equity-to-Asset of 0.21 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on HCW Biologics and its competitors. This is 69% below median its historical median of 0.68. According to the industry distribution chart, HCW Biologics ranks #1161 out of 1416 companies in the Biotechnology industry, placing it in the top 82%.
Is HCW Biologics' Equity-to-Asset too high?
HCW Biologics' current Equity-to-Asset of 0.21 is 69% below median its 10-year median of 0.68. The Biotechnology industry median Equity-to-Asset is 0.68. HCW Biologics' value of 0.21 is 69.1% below this industry median. Based on the distribution chart, HCW Biologics ranks #1161 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, HCW Biologics has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' Equity-to-Asset compare to GOVX and GLMD?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #1161 out of 1416 companies for Equity-to-Asset. This places HCW Biologics in the lower half of its industry. The industry median Equity-to-Asset is 0.68. HCW Biologics' value of 0.21 is 69.1% below this benchmark. While the company's 10-year median is 0.68 vs. the industry median of 0.68, HCW Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HCW Biologics's current Equity-to-Asset of 0.21 is 69.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on HCW Biologics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCW Biologics's current Equity-to-Asset is 0.21, which is 69% below median its own 10-year median of 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $43.71, compared to a current price of $3.34 — trading 92.4% below its estimated fair value. The current Equity-to-Asset is 0.21, which is 69% below median its 10-year median of 0.68 and 69.1% below the Biotechnology industry median of 0.68. HCW Biologics' overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For HCW Biologics (HCWB), the current Equity-to-Asset is 0.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $3.34 is trading 92.4% below its estimated GF Value™ of $43.71.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
Equity-to-Asset: 0.21 (69% below median its 10-year median of 0.68)
GF Value™: $43.71 vs. price of $3.34 (92.4% below fair value)
Industry Position: 69.1% below the Biotechnology median (#1161 of 1416)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
37GF Score
Get the complete analysis for HCWB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 
